<DOC>
	<DOCNO>NCT01342289</DOCNO>
	<brief_summary>This research do learn nonmyeloablative bone marrow transplantation ( BMT ) , also know `` mini '' transplant patient blood cancer , use bone marrow relative .</brief_summary>
	<brief_title>Shorter Course Tacrolimus After Nonmyeloablative , Related Donor BMT With High-dose Posttransplantation Cyclophosphamide</brief_title>
	<detailed_description>The main goal learn whether drug call tacrolimus , immune-lowering drug ( immunosuppressant ) give transplant help prevent certain complication , give safely short period time past . At present time cure type disease outside bone marrow transplant . The bone marrow transplant come relative half-match `` haplo '' match . Possible donor include parent , sibling , child . In order help bone marrow grow , `` take '' , inside body , receive chemotherapy radiation transplant . After transplant receive high dos cyclophosphamide ( CytoxanÂ® ) along medication low immune system , tacrolimus . These medication may lower risk graft versus host disease ( GVHD ) body reject bone marrow graft .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . 0.575 year 2 . Suitable firstdegree relate , HLA haploidentical HLAmatched donor 3 . Eligible diagnosis : a. Lowgrade nonHodgkin 's lymphoma plasma cell neoplasm either following , stable disease well prior transplantation : i. Progressed multiagent therapy , fail least two prior therapy ( exclude single agent rituximab ) , evidence prior transformation ii . SLL CLL 11q 17p deletion progression &lt; 6 month purine analogcontaining regimen b. Relapsed , refractory , progressive aggressive non Hodgkin 's lymphoma ( include mantle cell lymphoma ) , PR good prior transplantation , autologous BMT recommend . Note : Patients Burkitt 's , atypical Burkitt 's , acute lymphoblastic lymphoma must CR . c. Relapsed , refractory , progressive Hodgkin 's lymphoma meeting one following criterion , autologous BMT recommend : i. PR good prior transplantation . ii . Stable disease prior transplantation , provide disease lowvolume disease control regard sufficient proceed BMT . Eligibility patient determine casebycase basis PI coPI . d. One follow poorrisk lymphoma plasma cell neoplasms , PR good prior transplantation : . Transformed lymphoma ii . Tcell PLL iii . Peripheral Tcell lymphoma iv . NK NK/Tcell lymphoma v. Blastic/blastoid mantle cell lymphoma vi . Plasma cell leukemia e. For patient SLL , CLL , PLL , &lt; 20 % bone marrow cellularity involve process ( low risk graft rejection ) . f. Relapsed , refractory , progressive acute leukemia second subsequent remission , remission define &lt; 5 % bone marrow blast morphologically . g. Poorrisk acute leukemia first remission , remission define &lt; 5 % bone marrow blast morphologically : i. AML least one following : AML arise MDS myeloproliferative disorder , secondary AML Presence Flt3 internal tandem duplication Poorrisk cytogenetics Primary refractory disease ii . ALL ( leukemia and/or lymphoma ) least one following : Poorrisk cytogenetics Clear evidence hypodiploidy Primary refractory disease iii . Biphenotypic leukemia h. MDS least one follow poorrisk feature : i. Poorrisk cytogenetics ii . IPSS score INT2 great iii . Treatmentrelated secondary MDS iv . MDS diagnose age 21 year v. Progression lack response standard DNAmethyltransferase inhibitor therapy vi . Lifethreatening cytopenia , include require frequent transfusion i. Interferon imatinibrefractory CML first chronic phase , CML second subsequent chronic phase j. Philadelphia chromosome negative myeloproliferative disease ( include myelofibrosis ) k. Chronic myelomonocytic leukemia l. Juvenile myelomonocytic leukemia 4 . One following : 1 . Cytotoxic chemotherapy , alemtuzumab , adequate course 5azacitidine decitabine must give within 3 month prior start condition 2 . Previous BMT within 6 month prior start condition . Note : Patients receive treatment outside window may eligible deemed sufficient reduce graft rejection risk ; decide casebycase basis PI coPI . 1 . Active extramedullary leukemia know active Central Nervous System ( CNS ) involvement malignancy . 2 . Previous Bone marrow transplant ( BMT ) less 3 month prior start condition . 3 . Inadequate endorgan function measure : 1 . Left ventricular ejection fraction less equal 35 % shorten fraction le 25 % 2 . Bilirubin great equal 3.0 mg/dL ( unless due Gilbert 's syndrome hemolysis ) , ALT AST great equal 5 x ULN 3 . FEV1 FVC less equal 40 % predict ; unable perform pulmonary function test due young age , oxygen saturation le 92 % room air 4 . Previous allogeneic BMT ( syngeneic BMT permissible ) . 5 . Pregnant breastfeeding . 6 . Uncontrolled infection .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Nonmyeloablative</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Bone Marrow Transplant ( BMT )</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>